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Abstract 293 cells were transfected with wild-type GSK3ß 
(WT-GSK3ß) or a mutant in which the PKB phosphorylation site 
(Ser-9) was altered to Ala (A9-GSK3ß). Upon stimulation with 
IGF-1 or insulin, WT-GSK3ß was inhibited 75% or 60%, 
respectively, whereas the activity of the A9-GSK3ß mutant was 
unaffected. Incubation of WT-GSK3ß with ΡΡ2Αχ (a Ser/Thr-
specific phosphatase) completely reversed the IGF-1- or insulin-
induced inhibition. IGF-1 stimulation did not induce any tv rosine 
dephosphorylation of WT-GSK3ß or A9-GSK3ß. Coexpression 
of WT-GSK3ß in 293 cells with either PKBa (also known as 
AKT) or PDK1 (the 'upstream' activator of PKB) mimicked the 
IGF-1- or insulin-induced phosphorylation of Ser-9 and inactiva-
tion of GSK3ß. 
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1. Introduction 
Glycogen synthase kinase-3 (GSK3) was originally identi-
fied as a protein kinase that phosphorylated and inactivated 
glycogen synthase, the enzyme which catalyses the last step in 
glycogen synthesis [1]. Subsequently, GSK3 was found to 
phosphorylate other proteins, including eIF2B (a nucleotide 
exchange factor required for the initiation of protein synthe-
sis) [2] and the microtubule-associated protein Tau [3]. Un-
usually for an extracellular signal-regulated protein kinase, 
GSK3 is fully active in unstimulated cells and is inhibited in 
response to insulin/IGF-1, growth factors and other signals 
(reviewed in [4,5]). The inactivation of GSK3 is likely to con-
tribute to the activation of glycogen synthesis [4] and protein 
synthesis [2] and to the dephosphorylation of Tau [3] that are 
induced by insulin/IGF-1. 
Stimulation of rat L6 myotubes with insulin/IGF-1 induces 
the phosphorylation of GSK3cc and GSK3ß at Ser-21 and 
Ser-9, respectively. Recent evidence suggests that these resi-
dues are phosphorylated by isoforms of protein kinase В 
(PKB) under these conditions [4]. The phosphorylation of 
these residues in vitro inactivates GSK3a/GSK3ß and inacti-
vation can be completely reversed by dephosphorylation cat-
alysed by Ser/Thr-specific protein phosphatases, such as PP1 
and PP2A [4]. 
In unstimulated cells GSK3 is also phosphorylated on a 
tyrosine residue (Tyr-279 in GSK3a and Tyr-216 in GSK3ß) 
which lies in the 'activation loop' between subdomains VII 
and VIII of the catalytic domain. This phosphotyrosine resi-
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due is essential for activity because its dephosphorylation with 
a protein tyrosine phosphatase (PTPase) inactivates GSK3 [6]. 
These findings raised the possibility that the inhibition of 
GSK3 by insulin, IGF-1 and other signals might not only 
be mediated by PKB-catalysed phosphorylation of Ser-21 
(GSK3a) and Ser-9 (GSK3ß), but also by a PTPase-catalysed 
dephosphorylation of Tyr-279 (GSK3a) and Tyr-216 
(GSK3ß). Several years ago it was reported that incubation 
of A431 cells with okadaic acid (an inhibitor of PP1/PP2A) 
inactivated GSK3 by promoting tyrosine dephosphorylation 
[7]. However, subsequent work showed that this was incorrect, 
because the okadaic acid-induced inactivation could be com-
pletely reversed by incubation of the GSK3 with PP1 [8]. 
More recently, it was reported that in Chinese hamster ovary 
(CHO) cells overexpressing the insulin receptor, the insulin-
induced inhibition of GSK3ß was accompanied by partial 
dephosphorylation of Tyr-216 and that a deletion mutant 
lacking the N-terminal nine residues of GSK3ß could still 
be inhibited partially by insulin [9]. 
In this paper, we have reinvestigated this question in human 
embryonic kidney 293 cells overexpressing wild-type GSK3ß 
(WT-GSK3ß) and a mutant in which Ser-9 has been changed 
to Ala (A9-GSK3ß). Our data indicate that the insulin/IGF-1 -
induced inhibition of GSK3ß is mediated solely by the phos-
phorylation of Ser-9 and not by dephosphorylation of Tyr-
216. We also provide further evidence that it is PKB which 
phosphorylates and inactivates GSK3ß in these cells, by dem-
onstrating that the overexpression of either PKB or 3-phos-
phoinositide-dependent protein kinase (PDK1, an 'upstream 
activator' of PKB [10,11]) is sufficient to induce phosphoryla-
tion of Ser-9 and the inactivation of GSK3ß. 
2. Materials and methods 
2.1. Materials 
Monoclonal antibodies recognising the sequence EFMPME (ЕЕ) 
were a gift from G. Walter (University of San Diego, CA, USA), 
and those recognising the (EQKLISEEDL) с-Мус (9E10) sequence 
were purchased from Boehringer (Lewes, UK). The antiphosphotyr-
osine antibody (PY120) was purchased from Transduction Laborato-
ries (Mamhead, UK). The secondary anti-mouse IgG conjugated to 
horseradish peroxidase was a gift of the Scottish Antibody Production 
Unit (Carluke, UK). Protein G-Sepharose was from Pharmacia (Mil-
ton Keynes, UK). For sources of other reagents see [5,12]. 
2.2. Construction of expression vectors 
A DNA construct expressing human GSK3ß with the EFMPME 
(ЕЕ) epitope tag at the N-terminus (WT-EE-GSK3ß) was prepared as 
follows. A standard PCR reaction was carried out using, as a tem-
plate, the human GSK3ß cDNA clone in the pBluescript SK+ vector 
(a gift of Dr. J. Woodgett, Ontario Cancer institute) and the oligo-
nucleotides GCGGTCCGGAACATAGTCCAGCACCAG and GC-
GGAGATCTGCCACCATGGAGTTCATGCCCATGGAGTCAG-
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GGCGGCCCAGAACC that incorporate a BspEl site and a Bglil 
site. A triple ligation was then set up in which the resulting PCR 
product was subcloned into the BgHl-Clal sites of the pCMV5 vector 
[13] as a Bglll-BspEl fragment, together with the C-terminal BspEl-
Clal fragment of GSK3ß. The structure of the construct was verified 
by DNA sequencing and purified using the Qiagen plasmid Mega kit 
according to the manufacturer's protocol. A GSK3ß construct in 
which Ser-9 was mutated to Ala and possessing a c-Myc epitope at 
the C-terminus (A9-Myc-GSK3ß) was prepared as in [14] and kindly 
provided in the pRMBS vector by Dr M. Goedert (MRC Laboratory 
of Molecular Biology, Cambridge, UK). The A9-Myc-GSK3ß gene 
was then subcloned into Xbal/EcoRl sites of the pCMV5 vector. 
The constructs for human haemagglutinin-tagged wild-type PKBa 
(HA-WT-PKBa), the K179A 'kinase dead' PKBa (HA-KD-PKBa) 
and the constitutively active PKBa (308D/473D PKBa) [15] and Myc-
PDK1 [11] have been described previously. 
2.3. Transfection of 293 cells and assay of GSK3 activity 
293 cells were cultured on 10 cm diameter dishes and transfected 
with 1 μg/ml pCMV5 DNA constructs encoding WT-EE-GSK3ß or 
A9-Myc-GSK3ß with or without HA-PKBa or Myc-PDKl using а 
modified calcium phosphate method [15]. 24 h post transfection, the 
cells were deprived of serum for a further 16 h, then stimulated for the 
times indicated with 100 ng/ml IGF-1 or insulin (100 nM) or buffer. 
Each dish of cells was lysed in 1.0 ml of ice-cold buffer A (50 mM 
Tris-HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton X-100, 
1 mM sodium oriÄopervanadate, 10 mM sodium glycerophosphate, 50 
mM sodium fluoride, 5 mM sodium pyrophosphate, 1 μΜ microcys-
tin-LR, 0.27 M sucrose, 1 mM benzamidine, 0.2 mM phenylmethyl-
sulphonyl fluoride, 10 μg/ml leupeptin, and 0.1% (v/v) 2-mercapto-
ethanol). The lysate was centrifuged at 4°C for 10 min at 13 000Xg 
and the supernatants (10 μg protein) incubated for 30 min on a shak-
ing platform with 5 μΐ of protein G-Sepharose coupled to 1 μg of 
either the ЕЕ antibody or the 9E10 Мус antibody in order to immu-
noprecipitate the WT-EE-GSK3ß and the A9-Myc-GSK3ß enzymes, 
respectively. The protein G-Sepharose-antibody-GSK3ß complex was 
washed twice with 1.0 ml of buffer A containing 0.5 M NaCl, and 
three times with buffer В (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA 
and 0.1% (v/v) 2-mercaptoethanol). The immunoprecipitates were in-
cubated with or without PP2Ai (25 mU/ml), and assayed using phos-
pho-GS peptide-1 [16]. One unit of activity was that amount of en-
zyme which phosphorylated 1 nmol of peptide in 1 min. One mU of 
PP2Ai was the amount of enzyme that dephosphorylated 1 nmol of 
glycogen phosphorylase in 1 min. 
2.4. Immunoprecipitation and assay PKB 
293 cells transfected with a DNA construct expressing either Myc-
PDKl or mock pCMV5 vector were stimulated with 100 ng/ml IGF-
1, and lysed with 1.0 ml of ice-cold buffer A. Each PKB isoform 
(ΡΚΒα, ΡΚΒβ and ΡΚΒγ) was then immunoprecipitated separately 
from 0.1 mg of cell lysate using isoform-specific antibodies [17] and 
assayed for activity using the peptide GRPRTSSFAEG [18]. 
2.5. Immunoblotting of GSK3ß immunoprecipitates 
Cell lysate (0.4 mg protein) was incubated for 30 min on a shaking 
platform at 4°C with 45 μΐ of protein G-Sepharose coupled covalently 
to either 90 μg of EE-antibody or 90 μg of Мус-antibody. The sus-
pension was centrifuged at 13000Xg, the GSK3 immunoprecipitates 
washed as described above, then denatured in 1% (by mass) SDS. 
Aliquots were electrophoresed on 10% SDS/polyacrylamide gels, 
transferred to nitrocellulose membranes, and immunoblotted with ap-
propriate antibodies. Detection was performed using the enhanced 
chemiluminescence reagent (Amersham). 
3. Results 
3.1. IGF-1 or insulin stimulation of cells inhibits GSK3ß by 
promoting phosphorylation of Ser-9 and not 
dephosphorylation of Tyr-216 
293 cells were transfected with D N A constructs expressing 
either WT-EE-GSK3ß or A9-Myc-GSK3ß. Both forms of 
G S K 3 were expressed at similar levels in unstimulated 293 
cells (data not shown) and possessed similar specific activities 
(Fig. 1). IGF-1 stimulation of 293 cells induced a 70% inhib-
ition of WT-EE-GSK3ß within 6 min. This increased to 75% 
inhibition after 20 min which was maintained for up to 1 h 
(Fig. 1). Incubation of WT-EE-GSK3ß from IGF-1-stimu-
lated cells with PP2Ai completely reversed this inhibition re-
turning WT-EE-GSK3ß to the specific activity observed in 
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Fig. 1. Effect of IGF-1 on the activity of wild-type GSK3ß and the A9 mutant. 293 cells were transiently transfected with DNA constructs ex-
pressing either WT-EE-GSK3ß or A9-Myc-GSK3ß. The cells were stimulated with 100 ng/ml IGF-1 for the times indicated and then lysed. 
The epitope-tagged GSK3ß was immunoprecipitated, incubated without or with 25 mU/ml PP2Ai and then assayed. GSK3ß activity is ex-
pressed as a reactivation ratio, i.e. GSK3 activity measured without PP2Ai treatment divided by GSK3 activity after PP2Ai treatment. The 
data are presented as the mean±S.E.M. for four separate experiments with each determination carried out in triplicate. No GSK3ß activity 
was obtained in mock transfections in which 293 cells were transfected with empty pCMV5 vector alone (data not shown). The specific activity 
of both WT-EE-GSK3ß and A9-Myc-GSK3ß obtained after immunoprecipitation from unstimulated cells followed by treatment with PP2Ai 
was 0.410.06 U/mg for both forms of GSK3. 
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Fig. 2. IGF-1 does not affect the tyrosine phosphorylation of GSK3ß. 293 cells were transiently transfected with DNA constructs expressing ei-
ther WT-EE-GSK3ß (A) or A9-Myc-GSK3ß (В). The cells were stimulated with 100 ng/ml IGF-1 for the times indicated and then lysed. The 
epitope-tagged GSK3ß was immunoprecipitated from 400 μg of lysate using either the Мус or ЕЕ antibodies coupled covalently to protein G-
Sepharose. Aliquots of the immunoprecipitates corresponding to 150 μg lysate protein were electrophoresed on 10% SDS/polyacrylamide gels, 
transferred to nitrocellulose and immunoblotted with anti-EE, anti-Myc or anti-phosphotyrosine (pY) antibodies. No GSK3ß immunoreactive 
band was observed in mock transfections using empty pCMV5 vector alone (data not shown). The results shown are representative of three in-
dependent experiments. 
unstimulated 293 cells after PP2Ai treatment (Fig. 1). Similar 
results were obtained when insulin (100 nM) was used instead 
of IGF-1. Insulin induced a 60% inhibition of WT-EE-GSK3ß 
after 5 min which was also reversed by PP2Ai (data not 
shown). IGF-1 stimulation also inhibited the endogenous 
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GSK3 in 293 cells by 50%, and this inhibition was fully re-
versed by PP2Ai (data not shown). 
In contrast, IGF-1 stimulation of cells expressing A9-Myc-
GSK3ß did not result in any inhibition of the A9-Myc-
GSK3ß activity, nor was the A9-Myc-GSK3ß activity in these 
immunoprecipitates further activated by incubation with 
PP2Aj (Fig. 1). 
Stimulation with IGF-1 did not cause any significant 
change in the tyrosine phosphorylation of WT-EE-GSK3ß 
or A9-Myc-GSK3ß, as judged by immunoblotting experi-
ments using an anti-phosphotyrosine antibody (Fig. 2). 
3.2. GSK3ß is phosphorylated at Ser-9 and becomes inhibited 
after cotransfection with either PKB or PDK1 
293 cells were transfected with DNA constructs expressing 
either WT-EE-GSK3ß or A9-Myc-GSK3ß in the presence or 
absence of DNA constructs expressing WT-HA-PKBa, or 
constitutively active PKBoc (308D/473D-HA-PKBcc) or cata-
lytically inactive PKBoc (KD-HA-PKBa). Coexpression of 
WT-EE-GSK3ß with either WT-HA-PKBa or 308D/473D-
HA-PKBa decreased activity by 68% and 85%, respectively, 
compared to cells transfected with WT-EE-GSK3ß and KD-
HA-PKBa or WT-EE-GSK3ß alone (Fig. ЗА). In contrast, 
A9-Myc-GSK3ß was not inactivated when coexpressed with 
WT-HA-PKBa or 308D/473D-HA-PKBa (Fig. 3B). 
WT-EE-GSK3ß could also be inhibited up to 50% by co-
transfection in 293 cells with Myc-PDKl, an 'upstream acti-
Fig. 3. WT-EE-GSK3ß is inactivated by cotransfection with PKBct. 
293 cells were transiently transfected with the PCMV5 vector ex-
pressing WT-EE-GSK3ß (A) or A9-Myc-GSK3ß (В) with or with-
out constructs expressing wild-type WT-HA-PKBa, 'kinase dead' 
KD-HA-PKBa or a constitutively active 308D/473D PKBa. GSK3ß 
was assayed after immunoprecipitation from the lysates and incuba-
tion with or without 25 mU/ml PP2Ai. GSK3ß activity is expressed 
as a reactivation ratio, i.e. GSK3ß activity measured without ΡΡ2Αχ 
treatment divided by GSK3 activity after PP2Ai treatment. The 
data are presented as the mean±S.E.M. for three separate experi-
ments with each determination carried out in triplicate. No GSK3ß 
activity was obtained in mock transfections in which 293 cells were 
transfected with empty pCMV5 vector alone (data not shown). The 
specific activities of WT-EE-GSK3ß and A9-Myc-GSK3ß after co-
transfection with HA-PKBa and reactivation with PP2Ai were both 
0.25 ± 0.06 U/mg. 
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Fig. 4. GSK3ß is inactivated by cotransfection with PDK1. 293 cells 
were transfected with DNA constructs expressing either WT-EE-
GSK3ß or A9-Myc-GSK3ß with or without Myc-PDKl. The cells 
were then stimulated for 5 min with or without 100 ng/ml IGF-1 
and lysed, and the tagged GSK3ß immunoprecipitated and assayed 
as in Fig. 1. The data are presented ±S.E.M. for four experiments 
with each determination carried out in triplicate. The specific activ-
ities of WT-EE-GSK3ß and A9-Myc-GSK3ß after cotransfection 
with Myc-PDKl and reactivation with PP2Ai were both 1.810.2 
U/mg. The level of transfected PDK1 was similar in all transfections 
(data not shown). 
vator' of PKB, and the inhibition was fully reversed by PP2Ai 
(Fig. 4). In contrast A9-Myc-GSK3ß was not inactivated by 
cotransfection with Myc-PDKl and ΡΡ2Αχ (Fig. 4). 
The inhibition of WT-EE-GSK3ß by cotransfection with 
Myc-PDKl suggested that the transfected PDK1 had acti-
vated the endogenous PKB in 293 cells which had then inac-
tivated the transfected GSK3. This was confirmed by immu-
noprecipitating each PKB isoform from the lysates of 293 cells 
cotransfected with WT-EE-GSK3ß and Myc-PDKl. These 
experiments revealed that Myc-PDKl had activated PKBa 
and ΡΚΒγ, the latter being the dominant isoform present. 
There was hardly any PKBß activity detectable in 293 cells 
transfected with PDK1 (Fig. 5). 
4. Discussion 
In this paper we have demonstrated that the inhibition of 
transfected or endogenous GSK3 by IGF-1 or insulin in 293 
cells is mediated solely by the phosphorylation of Ser-9. Thus 
the inhibition could be fully reversed by incubation with 
PP2Ab and did not occur if Ser-9 was mutated to Ala (Fig. 
1). These results are supported by the finding that the inhib-
ition of GSK3 isoforms by insulin can be fully reversed by 
treatment with Ser/Thr-specific protein phosphatases in rat L6 
myotubes [18], rat skeletal muscle [12], rat adipocytes [12,19] 
or human myoblasts [20]. Murai et al. [9] reported that the 
insulin-induced inhibition of GSK3 in CHO cells overexpress-
ing the insulin receptor could not be fully reversed by PP2A, 
but Welsh et al. [2,21] reported full reactivation of GSK3 in 
the same cell line. The inhibition of GSK3 induced by EGF or 
okadaic acid in A431 cells [8] can also be fully reversed by Ser/ 
Thr-specific protein phosphatases [8]. The Ala-9 mutant of 
GSK3ß has also been overexpressed in cells by others, and 
was also not inhibited by insulin/IGF-1 stimulation of neuro-
nal NT2N cells [22] or after TPA stimulation of HeLa cells 
[23]. 
We were unable to detect any significant change in the 
phosphotyrosine content of either the wild-type or Ala-9 mu-
tant of GSK3 after stimulation of transfected 293 cells with 
IGF-1 (Fig. 2), consistent with the inhibition of GSK3ß being 
mediated solely by the phosphorylation of Ser-9. This conclu-
sion is also consistent with experiments using insulin-stimu-
lated L6 myotubes, in which the only tryptic peptide from 
GSK3 whose 32P-content was altered was that containing 
Ser-21 (GSK3a) or Ser-9 (GSK3ß) [18]. The 32P-labelling of 
the phosphotyrosine-containing tryptic peptide from GSK3a 
or GSK3ß was also unaffected by EGF stimulation of A431 
cells [8]. We were unable to obtain any evidence in support of 
the work of Murai et al. [9] who reported that the tyrosine 
phosphorylation of GSK3 decreased in response to insulin in 
CHO cells and in response to EGF or phorbol esters in COS 
cells. 
The protein kinase responsible for phosphorylating Tyr-216 
(GSK3ß) or Tyr-279 (GSK3cc) in vivo is unclear. Some tyro-
sine phosphorylation was detected when the ß-isoform was 
expressed in E. coli [24], suggesting that GSK3 is capable of 
autophosphorylating itself at Tyr-216, but this does not ex-
clude the possibility that another protein kinase phosphoryl-
ates this residue in vivo. If the tyrosine phosphorylation of 
GSK3 occurs in vivo by autophosphorylation, then it might 
be predicted that the inhibition of GSK3 resulting from serine 
phosphorylation might be followed by a slower dephospho-
rylation of the tyrosine residue. However, we were unable to 
detect any decrease in tyrosine phosphorylation up to 1 h 
after stimulation with IGF-1 (Fig. 2), even though the inhib-
ition of GSK3 was nearly maximal after 6 min (Fig. 1). This 
suggests that the dephosphorylation of Tyr-216 is very slow or 
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Fig. 5. ΡΚΒα and ΡΚΒγ are activated by transfection of PDK1 into 
293 cells. 293 cells were transiently transfected with DNA constructs 
expressing Myc-PDKl. The cells were stimulated with or without 
100 ng/ml IGF-1, lysed and the endogenous ΡΚΒα, ΡΚΒβ and 
ΡΚΒγ immunoprecipitated individually from the cell lysates (100 μg 
of protein) and assayed. The results are presented as PKB activity 
(mU/mg) ± S.E.M. for five separate experiments, with each determi-
nation carried out in triplicate. The efficiency of Myc-PDK-1 trans-
fection into these cells was calculated as 60%. Therefore the data 
were corrected to take this into account (by multiplying the ob-
served PKB activity in cells transfected with Myc-PDK-1 by a fac-
tor of 1.67). 
M. Shaw et al.lFEBS Letters 416 (1997) 307-311 311 
that GSK3ß is phosphorylated at Tyr-216 in vivo by another 
enzyme that is not inactivated by IGF-1. 
Coexpression of GSK3ß together with wild-type PKBa or а 
constitutively activated form of PKBa resulted in 70% and 
85% inhibition of GSK3ß activity, respectively, in unstimu-
lated 293 cells (Fig. 3). This inhibition could be fully reversed 
by ΡΡ2Αχ and did not occur when Ser-9 was mutated to Ala. 
In contrast, a catalytically inactive mutant of PKBa did not 
inactivate GSK3ß (Fig. 3). This shows for the first time that 
PKBa is capable of phosphorylating Ser-9 and inhibiting 
GSK3 in a cellular context. The inhibition of transfected 
GSK3ß by wild-type PKB in unstimulated 293 cells can be 
explained by the very high level of expression of PKB in 293 
cells (20-fold higher than GSK3ß - data not shown) under 
these conditions. Hence a significant level of basal PKB ac-
tivity is present in these cells. 
The full activation of PKBa by insulin/IGF-1 requires its 
phosphorylation at Thr-308 and Ser-473 [15]. The phosphoryl-
ation of Thr-308 appears to be catalysed in vivo by PDK1, 
while Ser-473 is phosphorylated by a distinct enzyme that has 
yet to be identified and characterised [10,11]. We have previ-
ously demonstrated that cotransfection of PDK1 and PKBa 
in unstimulated 293 cells induced a partial activation of PKBa 
that resulted from the phosphorylation of Thr-308 [11]. In the 
present study we have demonstrated that transfected GSK3ß 
becomes inhibited by Ser-9 phosphorylation following co-
transfection with PDK1 (Fig. 4). This appears to be mediated 
by the activation of the endogenous PKB isoforms (princi-
pally PKBa and ΡΚΒγ) present in 293 cells (Fig. 5). The 
experiments presented in this paper support the contention 
that PDK1, PKB and GSK3 comprise a protein kinase cas-
cade that is likely to be important in mediating many of the 
intracellular effects of insulin/IGF-1. 
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